Oveporexton Research for Narcolepsy Type 1
An evidence-based overview of research examining Oveporexton in the context of narcolepsy type 1. This page synthesizes findings from peer-reviewed literature.
Research Summary
Oveporexton is specifically developed for NT1, caused by autoimmune destruction of orexin-producing neurons. The Phase 2 trial TAK-861-2001 (NCT05687903, NEJM 2025) demonstrated significant improvements in MWT sleep latency (primary), ESS, and weekly cataplexy rate; Phase 3 trials (NCT06470828, NCT06505031) are completed with results pending publication. FDA Breakthrough Therapy designation.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Oveporexton may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.